Cancer Pain Therapeutic and Drug Pipeline Review H1.pdf

Text-only Preview

Report Information
More information from: https://www.wiseguyreports.com/reports/515131
Cancer Pain - Pipeline Review, H1 2016
Report / Search Code: WGR515131 Publish Date: 25 May, 2016
Price 1-user PDF : $ 2000.0 Site PDF : $ 4000.0 Enterprise PDF : $ 6000.0
Description: Cancer Pain - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Cancer Pain - Pipeline Review, H1 2016’, provides an overview of the
Cancer Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cancer
Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview of key players
involved in therapeutic development for Cancer Pain and features dormant and discontinued
projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using data and information sourced
from Global Markets Direct’s proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug profiles featured in the
report undergoes periodic review following a stringent set of processes to ensure that all the
profiles are updated with the latest set of information. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research
institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-
registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Cancer Pain therapeutics and enlists all their major and
minor projects
- The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cancer Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective
R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-
strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for
Cancer Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising
pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth
and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Contents: Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Cancer Pain Overview 12
Therapeutics Development 13
Pipeline Products for Cancer Pain - Overview 13
Pipeline Products for Cancer Pain - Comparative Analysis 14
Cancer Pain - Therapeutics under Development by Companies 15
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 17
Cancer Pain - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Cancer Pain - Products under Development by Companies 22
Cancer Pain - Products under Investigation by Universities/Institutes 24
Cancer Pain - Companies Involved in Therapeutics Development 25
AngioChem Inc. 25
Aphios Corporation 26
AstraZeneca Plc 27
BCN Peptides, S.A. 28
Benitec Biopharma Limited 29
BioDelivery Sciences International, Inc. 30
ChironWells GmbH 31
Daewoong Pharmaceutical Co., Ltd. 32
Daiichi Sankyo Company, Limited 33
Fujimoto Pharmaceutical Corporation 34
Grunenthal GmbH 35
GW Pharmaceuticals Plc 36
Hisamitsu Pharmaceutical Co., Inc. 37
Immupharma Plc 38
IntelGenx Corp. 39
Kineta, Inc. 40
Kolon Life Science, Inc. 41
Neurocentrx Pharma Ltd. 42
Nippon Kayaku Co., Ltd. 43
Orion Oyj 44
Pain Therapeutics, Inc. 45
Pfizer Inc. 46
Pharmaleads SA 47
Recordati S.p.A. 48
Ribomic Inc. 49
Trillium Therapeutics Inc. 50
Virobay Inc. 51
WEX Pharmaceuticals Inc. 52
Zynerba Pharmaceuticals, Inc. 53
Cancer Pain - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ANG-2002 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AQU-118 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BBI-11008 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
buprenorphine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
cebranopadol - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
crotalphine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CSTI-200 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DD-04107 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dexmedetomidine hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
dronabinol - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
dronabinol - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Drug for Cancer Neuropathic Pain - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
DWJ-208 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
fentanyl - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
fentanyl citrate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
fentanyl citrate - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
fentanyl citrate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HP-3150 - Drug Profile 84
Product Description 84
Mechanism of Action 84